Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study-Reference-Cited by-同舟云学术

Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study

Published:2020-11 Issue: Volume:161 Page:105127
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Tian Jiaxing,Yan Shiyan,Wang Han,Zhang Ying,Zheng Yujiao,Wu Haoran,Li Xiuyang,Gao Zezheng,Ai Yanke,Gou Xiaowen,Zhang Lei,He Liyun,Lian Fengmei,Liu Baoyan,Tong Xiaolin

Funder

pecial Project for Emergency of the Ministry of Science and Technology

raditional Chinese Medicine Special Project for COVID-19 Emergency of National Administration of Traditional Chinese Medicine

Publisher

Elsevier BV

Subject

Pharmacology

Reference25 articles.

1. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle;Lu;J. Med. Virol.,2020

2. Notice Concerning the Recommendation of the Prescription of Traditional Chinese Medicine in the Treatment of COVID-19;Medical treatment group of Wuhan COVID - 19 prevention and control headquarters,2020

3. Discussion on traditional chinese medicine prevention and treatment strategies of coronavirus disease 2019 (COVID-19) from the perspective of “Cold-dampness pestilence”;Tong;J. Tradit. Chin. Med.,2020

4. Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management;National Health Commission of the People’s Republic of China,2020

5. World health organization. Coronavirus disease (COVID-19) Situation dashboard. https://who.sprinklr.com/.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-19;Engineering;2024-07

2. Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir–ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial;Science Bulletin;2024-06

3. Effect of Chinese Medicine in Patients with COVID-19: A Multi-center Retrospective Cohort Study;Chinese Journal of Integrative Medicine;2024-05-31

4. Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19;Frontiers of Medicine;2023-12-29

5. The rational dose for MaXingShiGan decoction is crucial for its clinical effectiveness in treating bronchial pneumonia: three randomized, double-blind, dose-parallel controlled clinical studies;Frontiers in Pharmacology;2023-11-23